BR112013032723A2 - antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 - Google Patents
antígenos amplamente reativos computacionalmente otimizados para influenza h1n1Info
- Publication number
- BR112013032723A2 BR112013032723A2 BR112013032723A BR112013032723A BR112013032723A2 BR 112013032723 A2 BR112013032723 A2 BR 112013032723A2 BR 112013032723 A BR112013032723 A BR 112013032723A BR 112013032723 A BR112013032723 A BR 112013032723A BR 112013032723 A2 BR112013032723 A2 BR 112013032723A2
- Authority
- BR
- Brazil
- Prior art keywords
- optimized
- polypeptides
- influenza
- reactive antigens
- immune response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo patente de invenção: "antígenos amplamente reativos computacionalmente otimizados para influenza h1n1". é descrita aqui a geração de polipeptídeos de ha de influenza h1n1 otimizados para induzir uma resposta imune amplamente reativa a isolados do vírus da influenza h1n1. os polipeptídeos de ha otimizados foram desenvolvidos através de uma série de alinhamentos de proteínas ha e subsequente geração de sequências de consenso com base em vírus h1n1 selecionados isolados em 1918-2011. são fornecidos aqui polipeptídeos de ha de h1n1 otimizados e composições, proteínas de fusão e vlps compreendendo os polipeptídeos de ha. ainda fornecidas são sequências de ácido nucleico com códon otimizado que codificam os polipeptídeos de ha. métodos de indução de uma resposta imune contra o vírus da influenza em um indivíduo são também fornecidos pela presente descrição. 20071021v1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498800P | 2011-06-20 | 2011-06-20 | |
PCT/US2012/043347 WO2012177760A1 (en) | 2011-06-20 | 2012-06-20 | Computationally optimized broadly reactive antigens for h1n1 influenza |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013032723A2 true BR112013032723A2 (pt) | 2017-01-31 |
Family
ID=47422918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013032723A BR112013032723A2 (pt) | 2011-06-20 | 2012-06-20 | antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 |
Country Status (10)
Country | Link |
---|---|
US (3) | US9580475B2 (pt) |
EP (2) | EP3199545B1 (pt) |
JP (2) | JP6113155B2 (pt) |
KR (1) | KR20140047069A (pt) |
CN (2) | CN106995488A (pt) |
AU (2) | AU2012273039B2 (pt) |
BR (1) | BR112013032723A2 (pt) |
CA (1) | CA2839995A1 (pt) |
RU (1) | RU2612900C2 (pt) |
WO (1) | WO2012177760A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US8883171B2 (en) * | 2010-09-14 | 2014-11-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9580475B2 (en) * | 2011-06-20 | 2017-02-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for H1N1 influenza |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
MX2014009148A (es) | 2012-02-07 | 2014-09-22 | Univ Pittsburgh | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h3n2, h2n2 y b. |
JP6175452B2 (ja) | 2012-02-13 | 2017-08-02 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | ヒトおよびトリh5n1インフルエンザのための、計算で最適化した反応性の広い抗原 |
EP2831094B1 (en) | 2012-03-30 | 2018-06-13 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
AU2013352179B2 (en) * | 2012-11-27 | 2017-12-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for H1N1 influenza |
CN105007938A (zh) * | 2013-03-15 | 2015-10-28 | 宾夕法尼亚大学理事会 | 流感核酸分子和由其制备的疫苗 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
JP6881813B2 (ja) | 2014-04-23 | 2021-06-02 | モデルナティーエックス, インコーポレイテッド | 核酸ワクチン |
WO2015184272A2 (en) | 2014-05-30 | 2015-12-03 | Sanofi Pasteur Biologics Llc | Expression and conformational analysis of engineered influenza hemagglutinin |
WO2016100926A1 (en) * | 2014-12-19 | 2016-06-23 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
US10927151B2 (en) * | 2015-06-09 | 2021-02-23 | Sanofi Pasteur Inc. | Methods of optimizing nucleotide sequences encoding engineered influenza proteins |
CA3003103A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
BR112018075078A2 (pt) | 2016-06-03 | 2019-03-06 | Sanofi Pasteur Inc. | modificação de polipeptídeos da hemaglutinina do influenza manipulados |
KR101906457B1 (ko) * | 2016-10-28 | 2018-10-12 | 성신여자대학교 산학협력단 | H5 조류 인플루엔자 바이러스 유사입자 백신 및 그 제조방법 |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
CN112189019A (zh) * | 2018-03-28 | 2021-01-05 | 圣诺菲·帕斯图尔公司 | 产生包含血凝素的广泛保护性疫苗组合物的方法 |
JP2021519596A (ja) | 2018-04-03 | 2021-08-12 | サノフイSanofi | フェリチンタンパク質 |
WO2019195284A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic influenza-ferritin polypeptides |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ES2320315T5 (es) | 1994-07-15 | 2012-12-05 | University Of Iowa Research Foundation | Oligonucleótidos inmunoestimuladores |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
CN101353375A (zh) * | 1995-05-26 | 2009-01-28 | Mg-Pmc有限公司 | 生产流感血凝素多价疫苗的方法 |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
DE69935507T2 (de) | 1998-04-03 | 2007-12-06 | University Of Iowa Research Foundation | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
EP1418940A4 (en) | 2000-03-02 | 2006-09-20 | Univ Emory | DNA expression vectors and methods of use |
WO2002000885A2 (en) | 2000-06-23 | 2002-01-03 | American Cyanamid Company | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
EP1851238A4 (en) | 2005-02-24 | 2008-12-31 | Univ Massachusetts | FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF |
CN101227920A (zh) | 2005-07-19 | 2008-07-23 | 陶氏环球技术公司 | 重组流感疫苗 |
WO2007072214A2 (en) | 2005-12-19 | 2007-06-28 | Novartis Vaccines And Diagnostics Srl | Methods of clustering gene and protein sequences |
WO2007092792A2 (en) * | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
US20080045472A1 (en) | 2006-03-31 | 2008-02-21 | Council Of Scientific And Industrial Research Bharat Biotech | Targets for human micro rnas in avian influenza virus (h5n1) genome |
WO2007130327A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Influenza virus-like particle (vlp) compositions |
US8980281B2 (en) | 2006-09-05 | 2015-03-17 | Academia Sinica | High-yield transgenic mammalian expression system for generating virus-like particles |
MX2009002174A (es) | 2006-09-07 | 2009-03-12 | Crucell Holland Bv | Moleculas de union humanas capaces de neutralizar el virus de la influenza h5n1 y usos de las mismas. |
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
EA017887B1 (ru) * | 2007-08-02 | 2013-03-29 | Байондвакс Фармасьютикалз Лтд. | Полимерные мультиэпитопные вакцины против гриппа |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
KR101255419B1 (ko) * | 2007-11-12 | 2013-04-17 | 이노비오 파마수티컬즈, 인크. | 인플루엔자 바이러스의 다중 아형에 대한 신규 백신 |
SG187500A1 (en) | 2008-01-21 | 2013-02-28 | Medicago Inc | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
US7981428B2 (en) | 2008-01-23 | 2011-07-19 | Academia Sinica | Flu vaccines and methods of use thereof |
US20120034253A1 (en) | 2008-09-25 | 2012-02-09 | Fraunhofer Usa, Inc. | Influenza Vaccines, Antigens, Compositions, and Methods |
WO2010036948A2 (en) * | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
CN102428099B (zh) | 2009-04-03 | 2016-03-16 | 梅里亚有限公司 | 运载新城疫病毒的禽疫苗 |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
US8883171B2 (en) | 2010-09-14 | 2014-11-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
US9580475B2 (en) * | 2011-06-20 | 2017-02-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for H1N1 influenza |
MX2014009148A (es) | 2012-02-07 | 2014-09-22 | Univ Pittsburgh | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h3n2, h2n2 y b. |
JP6175452B2 (ja) | 2012-02-13 | 2017-08-02 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | ヒトおよびトリh5n1インフルエンザのための、計算で最適化した反応性の広い抗原 |
EP2831094B1 (en) | 2012-03-30 | 2018-06-13 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses |
AU2013352179B2 (en) * | 2012-11-27 | 2017-12-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for H1N1 influenza |
-
2012
- 2012-06-20 US US14/126,550 patent/US9580475B2/en active Active
- 2012-06-20 EP EP17161197.3A patent/EP3199545B1/en active Active
- 2012-06-20 AU AU2012273039A patent/AU2012273039B2/en not_active Ceased
- 2012-06-20 JP JP2014517123A patent/JP6113155B2/ja not_active Expired - Fee Related
- 2012-06-20 BR BR112013032723A patent/BR112013032723A2/pt active Search and Examination
- 2012-06-20 RU RU2014101401A patent/RU2612900C2/ru not_active IP Right Cessation
- 2012-06-20 EP EP12802232.4A patent/EP2721158B1/en active Active
- 2012-06-20 WO PCT/US2012/043347 patent/WO2012177760A1/en active Application Filing
- 2012-06-20 CA CA2839995A patent/CA2839995A1/en not_active Abandoned
- 2012-06-20 KR KR1020147000840A patent/KR20140047069A/ko not_active Application Discontinuation
- 2012-06-20 CN CN201710128479.0A patent/CN106995488A/zh active Pending
- 2012-06-20 CN CN201280039877.0A patent/CN103732749B/zh not_active Expired - Fee Related
-
2016
- 2016-05-02 JP JP2016092342A patent/JP2016183168A/ja active Pending
-
2017
- 2017-01-17 US US15/407,502 patent/US10093703B2/en active Active
- 2017-02-28 AU AU2017201381A patent/AU2017201381A1/en not_active Abandoned
-
2018
- 2018-08-31 US US16/119,501 patent/US10562940B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016183168A (ja) | 2016-10-20 |
EP3199545A3 (en) | 2017-09-20 |
CA2839995A1 (en) | 2012-12-27 |
EP3199545B1 (en) | 2019-10-30 |
US9580475B2 (en) | 2017-02-28 |
AU2012273039A1 (en) | 2014-01-16 |
US10093703B2 (en) | 2018-10-09 |
JP2014519849A (ja) | 2014-08-21 |
EP3199545A2 (en) | 2017-08-02 |
EP2721158A4 (en) | 2015-06-10 |
US20140127248A1 (en) | 2014-05-08 |
CN103732749A (zh) | 2014-04-16 |
CN106995488A (zh) | 2017-08-01 |
KR20140047069A (ko) | 2014-04-21 |
AU2017201381A1 (en) | 2017-03-23 |
EP2721158B1 (en) | 2017-05-03 |
JP6113155B2 (ja) | 2017-04-12 |
WO2012177760A1 (en) | 2012-12-27 |
RU2014101401A (ru) | 2015-07-27 |
US20170121374A1 (en) | 2017-05-04 |
US20180371025A1 (en) | 2018-12-27 |
RU2612900C2 (ru) | 2017-03-13 |
US10562940B2 (en) | 2020-02-18 |
CN103732749B (zh) | 2017-03-29 |
AU2012273039B2 (en) | 2016-12-01 |
EP2721158A1 (en) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013032723A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 | |
BR112014018884A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b | |
MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
MX345150B (es) | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. | |
BR112013020070A8 (pt) | moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas | |
MX2013014109A (es) | Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria. | |
BR112013019975A2 (pt) | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" | |
BRPI1015053A2 (pt) | partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina | |
RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
EA201892795A1 (ru) | Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу | |
AU2013352179A8 (en) | Computationally optimized broadly reactive antigens for H1N1 influenza | |
MX2013003470A (es) | Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria. | |
WO2012082803A3 (en) | Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof | |
To et al. | Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A (H7N9) virus infection | |
RU2015140603A (ru) | Вакцины на основе нуклеопротеина вируса гриппа | |
Yang et al. | Protection against influenza H7N9 virus challenge with a recombinant NP–M1–HSP60 protein vaccine construct in BALB/c mice | |
Rostaminia et al. | Computational design and analysis of a multi-epitope against influenza A virus | |
EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
WO2012178078A3 (en) | Use of yscf, truncated yscf and yscf homologs as adjuvants | |
WO2013093514A2 (en) | Vaccines - peptides | |
ALAVI et al. | Over expression of influenza virus M2 protein in prokaryotic system | |
RU2757013C2 (ru) | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения | |
Sharma et al. | Immunoinformatics: Screening of Potential T Cell Antigenic Determinants in Proteome of H1N1 Swine In. uenza Virus for Virus Epitope Vaccine Design | |
RU2015140822A (ru) | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения | |
Attaran et al. | Immunogenicity and protective efficacy of recombinant M2e. Hsp70c (Hsp70 359–610) fusion protein against influenza virus infection in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2577 DE 26/05/2020 POR TER SIDO INDEVIDA. |